The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy.
 
Nai-Jung Chiang
No Relationships to Disclose
 
Her-Shyong Shiah
No Relationships to Disclose
 
Chia-Chi Lin
No Relationships to Disclose
 
Chia-Jui Yen
No Relationships to Disclose
 
Hui-Jen Tsai
No Relationships to Disclose
 
Shang-Yin Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Roche; Sanofi
 
Wu-Chou Su
No Relationships to Disclose
 
Kwang-Yu Chang
No Relationships to Disclose
 
Li-Tzong Chen
Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Merrimack; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Polaris (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - HuniLife